Katina Dorton's most recent trade in Prelude Therapeutics Inc was a trade of 76,000 Director Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Oct. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Oct 2025 | 76,000 | 76,000 | - | - | Director Stock Option (Right to Buy) | |
| Tscan Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 36,000 | 36,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Tscan Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 47,500 | 47,500 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Tscan Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Tscan Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 9,146 | 9,146 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) |